Impairment in functional status and survival in patients with acute myeloid leukaemia
- 5 July 2006
- journal article
- research article
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 132 (10) , 665-671
- https://doi.org/10.1007/s00432-006-0115-7
Abstract
Acute myeloid leukaemia (AML) is mainly affecting elderly patients. Elderly patients are increasingly affected by impairment of functional status (FS). FS is of prognostic relevance for survival in different tumours. Data for patients with AML are rare. Within a prospective trial we recruited patients with newly diagnosed AML and measured FS by two different methods: Karnofsky performance status (KPS) and instrumental activities of daily living (IADL). Sixty-three patients aged 19–85 years (median 61.1) were included. Twenty-three had prior myelodisplastic syndrome (MDS), 7 favourable, 17 unfavourable karyotype. Fifty received induction chemotherapy, 13 palliative chemotherapy. Median survival was 15.2 months (95% CI, 10.8–22.3) in all patients. Age, cytogenetic risk group, and impaired KPS and IADL significantly influenced median survival in univariate analysis. Impairment of IADL was the single most predictive variable. In multivariate analysis, impairment of IADL Score (HR:4.3, 95% CI 1.7–10.5, P = 0.001) and of KPS (HR:4.8, 95% CI 1.9–12.3, P = 0.001), and unfavourable cytogenetic risk group (HR:6.0, 95% CI 2.5–14.3, P < 0.001) significantly predicted median survival. In patients with AML, FS and not age is a major predictor of survival. The influence of FS is independent from cytogenetic risk group. IADL measurement adds information to KPS. The results have to be confirmed in a large sample of patients.Keywords
This publication has 22 references indexed in Scilit:
- Drug therapy for acute myeloid leukemiaBlood, 2005
- Disease biology rather than age is the most important determinant of survival of patients ≥ 60 years with acute myeloid leukemia treated with uniform intensive therapyCancer, 2005
- Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndromeLeukemia, 2004
- Elderly Patients with Acute Myeloid Leukaemia: Characteristics in Biology, Patients and Treatment. Recommendations of the Working Group Geriatric Oncology of the German Society for Haematology and Oncology (DGHO), the Austrian Society for Haematology and Oncology (ÖGHO) and the German Society for Geriatrics (DGG)Oncology Research and Treatment, 2004
- Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)Blood, 2002
- Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemiaBritish Journal of Haematology, 2001
- Acute Myeloid Leukemia in the Elderly: A Critical Review of Therapeutic Approaches and Appraisal of Results of TherapyLeukemia & Lymphoma, 1998
- AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trialBritish Journal of Haematology, 1989
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976
- The use of the nitrogen mustards in the palliative treatment of carcinoma.With particular reference to bronchogenic carcinomaCancer, 1948